Advertisement
Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
(RTTNews) - While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
For fiscal 2023, the company continues to project total revenue between $15.5 billion and $16.0 billion. On average, nine analysts polled by Thomson Reuters expect the company to report revenues of $15.60 billion for the year.
The company also said its Board of Directors declared a quarterly dividend of $0.12 for each issued and outstanding share of the company's common stock, payable on September 15, 2023, to shareholders of record at the close of business on August 24, 2023.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
Viatris Announces US Commercial Launch Of RYZUMVl 0.75%
Healthcare company Viatris Inc. (VTRS) announced Monday the U.S. commercial launch of RYZUMVI (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the U.S.
RTTNews
|
513 dias atrás
Viatris Guides FY24 In Line With Estimates - Update
While reporting financial results for the fourth quarter on Wednesday, healthcare company Viatris Inc. (VTRS) initiated its adjusted earnings and revenue guidance for the full-year 2024.
RTTNews
|
546 dias atrás
Viatris Reaffirms FY23 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the first quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2023.
RTTNews
|
842 dias atrás
Viatris To Acquire Oyster Point And Famy Life Sciences To Create Ophthalmology Franchise
Healthcare company Viatris Inc. (VTRS) announced Monday that it intends to create an ophthalmology franchise by acquiring Oyster Point Pharma and Famy Life Sciences.
RTTNews
|
1024 dias atrás
Viatris Reaffirms FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the third quarter on Monday, healthcare company Viatris Inc. (VTRS) reaffirmed its total revenue guidance for the full-year 2022 to solid operating momentum despite foreign exchange headwinds and absorbing inflation impact to date.
RTTNews
|
1024 dias atrás
U.S. District Court Rules In Favor Of Merck In Patent Infringement Suit Against Viatris
Merck (MRK), known as MSD outside of the United States and Canada, announced Thursday that the U.S. District Court for the Northern District of West Virginia ruled in favor of the company in a patent infringement suit against Viatris, Inc. (VTRS) related to sitagliptin, an active ingredient in JANUVIA, JANUMET and JANUMET XR.
RTTNews
|
1070 dias atrás
Viatris Trims FY22 Revenue Outlook, Declares Dividend - Update
While reporting financial results for the second quarter on Monday, healthcare company Viatris Inc. (VTRS) trimmed its total revenue guidance for the full-year 2022 to reflect the incremental impact of foreign exchange.
RTTNews
|
1115 dias atrás
Sensex Nifty Decline On Tariff Worries
Indian shares opened on a sluggish note on Thursday after U.S. President Donald Trump's 50 percent tariffs on Indian goods came into effect, impacting trade worth billions of dollars and risking Washington-New Delhi ties.
RTTNews
|
27 minutos atrás
